Tillkännagivande • May 05
Tryp Therapeutics to be Delisted from the Canadian Securities Exchange and to Stop Trading on the OTCQB Venture Market Following the Arrangement Tryp Therapeutics Inc. has been acquired by Exopharm Limited through an all-stock transaction, as the plan of arrangement has been finalized, allowing Tryp shareholders to exchange each of their shares for 3.616 Exopharm shares. Following the arrangement, Tryp will be delisted from the Canadian Securities Exchange and will stop trading on the OTCQB Venture Market. Exopharm shares are set to begin trading on the Australian Securities Exchange under the new name ‘Tryptamine Therapeutics Limited’ with the ticker ‘TYP’. Tillkännagivande • May 03
Tryp Therapeutics Inc. (CNSX:TRYP) completed the acquisition of Exopharm Limited (ASX:EX1) in a reverse merger transaction. Tryp Therapeutics Inc. (CNSX:TRYP) entered into a definitive agreement to acquire Exopharm Limited (ASX:EX1) for CAD 7.2 million in a reverse merger transaction on December 8, 2023. Pursuant to the agreement Exopharm has agreed to acquire all of the issued and outstanding common shares in the capital of Tryp (the “Tryp Shares”) in consideration of the issuance of 4.52 ordinary shares in the capital of Exopharm (the “Exopharm Shares”) for each one (1) Tryp Share. Pursuant to the arrangement agreement, holders of convertible securities of Tryp, including stock options, common share purchase warrants, secured convertible debentures and unsecured convertible notes (collectively, the “Tryp Convertible Securities”) will receive replacement securities of Exopharm having substantially similar economic terms in accordance with the rules of the ASX. The purchase price of CAD 0.08 per Tryp Share and aggregate transaction value of approximately CAD 12.8 million. The majority of the directors of the combined entity to be appointed by Tryp. The combined entity is expected to relist on the Australian Securities Exchange (the “ASX”) in Q1 2024 subject to, among other conditions, receipt of the requisite approval of Exopharm shareholders and raising a minimum of AUD 6,000,000 under a public offering. As of January 25, 2024, Tryp entered into an amendment to its arrangement agreement with Exopharm Limited. Under the revised terms, Exopharm will acquire all issued and outstanding common shares of Tryp, in exchange for 3.616 ordinary shares of Exopharm for each Tryp share, a change from the previously stated ratio of 4.52. Additionally, there will be a consolidation of Exopharm shares before completing the transaction, adjusting from a 2:1 to a 2.5:1 consolidation ratio.The Arrangement is subject to customary closing conditions, including approvals from Tryp securityholders and Exopharm shareholders, all other applicable third party, regulatory consents for the Arrangement, no more than 10% of the Company's shareholders exercising their rights of dissent in connection with the Arrangement, approvals from the ASX and the Supreme Court of British Columbia (the “Court”). Both the Board and the Special Committee unanimously recommend that Tryp securityholders vote in favor of the Arrangement, Exopharm Capital Raise. Tryp will pay termination fee of CAD 1 million while Exopharm shall pay CAD 0.2 million. Post acquisition, Exopharm will change its name to Tryptamine Therapeutics Australia Limited and the symbol TYP. As of March 8, 2024 Exopharm and Tryp Therapeutics Inc signed a Binding Arrangement Agreement. Pushor Mitchell LLP acted as legal counsel to Tryp in Canada and K&L Gates LLP acted as legal counsel to Tryp in Australia in connection with the Arrangement. Alan Hutchison of Osler, Hoskin & Harcourt LLP acted as legal counsel to Exopharm in Canada and Hamilton Locke Pty Ltd acted as legal counsel to Exopharm in Australia. ACNS Capital Markets Pty Ltd trading as Alto Capital acted as Exopharm’s corporate advisor in connection with the arrangements. Computershare Investor Services Inc. acted as a transfer agent of Tryp while Automic Pty Ltd. acted as a transfer agent of Exopharm.Tryp Therapeutics Inc. (CNSX:TRYP) completed the acquisition of Exopharm Limited (ASX:EX1) in a reverse merger transaction on May 1, 2024. Board Change • Mar 05
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Chris Ntoumenopoulos was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Chris Ntoumenopoulos was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Feb 11
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting Tryp Therapeutics Inc. announced that further to its press releases of December 11, 2023 and January 26, 2024, Tryp has obtained an interim order (the "Interim Order") of the Supreme Court of British Columbia in connection with the proposed arrangement between Tryp and Exopharm Limited ACN 163 765 991 to be implemented under a statutory plan of arrangement pursuant to section 288 of the Business Corporations Act (British Columbia). The Interim Order provides for the holding of an annual general and special meeting of Tryp securityholders to, among other things, consider and vote on a special resolution approving the Arrangement. New Risk • Feb 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.6m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-CA$4.9m). Revenue is less than US$1m. Market cap is less than US$10m (CA$3.74m market cap, or US$2.77m). Minor Risk Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Tillkännagivande • Dec 16
Tryp Therapeutics Inc., Annual General Meeting, Feb 16, 2024 Tryp Therapeutics Inc., Annual General Meeting, Feb 16, 2024. Tillkännagivande • Dec 12
Exopharm Limited (ASX:EX1) entered into a definitive agreement to acquire Tryp Therapeutics Inc. (CNSX:TRYP) for CAD 7.2 million. Exopharm Limited (ASX:EX1) entered into a definitive agreement to acquire Tryp Therapeutics Inc. (CNSX:TRYP) for CAD 7.2 million on December 8, 2023. Pursuant to the agreement Exopharm has agreed to acquire all of the issued and outstanding common shares in the capital of Tryp (the “Tryp Shares”) in consideration of the issuance of 4.52 ordinary shares in the capital of Exopharm (the “Exopharm Shares”) for each one (1) Tryp Share. Pursuant to the arrangement agreement, holders of convertible securities of Tryp, including stock options, common share purchase warrants, secured convertible debentures and unsecured convertible notes (collectively, the “Tryp Convertible Securities”) will receive replacement securities of Exopharm having substantially similar economic terms in accordance with the rules of the ASX. The purchase price of CAD 0.08 per Tryp Share and aggregate transaction value of approximately CAD 12.8 million. The majority of the directors of the combined entity to be appointed by Tryp. The combined entity is expected to relist on the Australian Securities Exchange (the “ASX”) in Q1 2024 subject to, among other conditions, receipt of the requisite approval of Exopharm shareholders and raising a minimum of AUD 6,000,000 under a public offering.
The Arrangement is subject to customary closing conditions, including approvals from Tryp securityholders and Exopharm shareholders, all other applicable third party, regulatory consents for the Arrangement, no more than 10% of the Company's shareholders exercising their rights of dissent in connection with the Arrangement, approvals from the ASX and the Supreme Court of British Columbia (the “Court”). Both the Board and the Special Committee unanimously recommend that Tryp securityholders vote in favor of the Arrangement.
Pushor Mitchell LLP acted as legal counsel to Tryp in Canada and K&L Gates LLP acted as legal counsel to Tryp in Australia in connection with the Arrangement. Osler, Hoskin & Harcourt LLP acted as legal counsel to Exopharm in Canada and Hamilton Locke Pty Ltd acted as legal counsel to Exopharm in Australia. ACNS Capital Markets Pty Ltd trading as Alto Capital acted as Exopharm’s corporate advisor in connection with the arrangements. Tillkännagivande • Nov 21
Tryp Therapeutics Inc. announced that it has received AUD 3.215 million in funding On November 20, 2023, Tryp Therapeutics Inc. closed the transaction. The company issued AUD 3.215 million in the transaction. Closing of the Private Placement is subject to final approval by the Canadian Securities Exchange. The securities issued in the Private Placement, including the common shares issuable on conversion of the Notes, will be subject to a hold period of four months and one day from the closing date of the Private Placement in accordance with applicable securities laws. The transaction included participation from new investor Jason Carroll for AUD 0.325 million. The company will pay 6% of proceeds raised under the Private Placement and will be issued such number of warrants as equals to 4.0% of the Common Shares issuable on conversion of the Notes. The transaction was oversubscribed. Tillkännagivande • Oct 12
Tryp Therapeutics Inc. announced that it has received AUD 0.175 million in funding On October 11, 2023, Tryp Therapeutics Inc. closed the transaction. Tillkännagivande • Oct 05
Tryp Therapeutics Inc. announced that it expects to receive AUD 0.175 million in funding Tryp Therapeutics Inc. announced a private placement of unsecured convertible debentures for gross proceeds of up to AUD 175,000 on October 4, 2023. The debentures will have a term of 12 months and will be interest free. The debentures shall automatically convert into common shares in the capital of the company on the earlier of the maturity date or the time the company is completing a liquidity event. The price at which the debentures will be converted into common shares will vary depending on various scenarios as set out in the debenture and at a conversion price fixed in accordance with CSE policies. Closing of the private placement is anticipated to occur on or about October 11, 2023, and is subject to receipt of all necessary corporate and regulatory approvals, including the approval of the Canadian Securities Exchange. The Debentures and the underlying common shares will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. Tillkännagivande • Aug 04
Tryp Therapeutics Announces Appointment of Jason Carroll as New Chief Executive Officer, Effective October 1, 2023 Tryp Therapeutics Inc. announced the appointment of Australia-based Jason Carroll as the Company's new Chief Executive Officer, beginning October 1, 2023. Mr. Carroll brings a wealth of experience as a highly regarded life sciences executive, with an impressive 32-year career in the industry. In addition to his most recent role as Managing Director of iNova Pharmaceuticals Philippines, his extensive background includes leadership roles at industry giants Johnson & Johnson, Janssen Pharmaceutica, and Bristol-Myers Squibb. Tillkännagivande • Aug 03
Tryp Therapeutics Inc. Announces the Passing of David Tousley, Director Tryp Therapeutics Inc. announced the passing of Mr. David Tousley, Director of Tryp and Chair of Tryp's Audit Committee. Dave was a highly experienced director who provided the Board with consistent, sage advice. His input was always well-reasoned and practical on issues brought to the Board. He worked tirelessly on behalf of TRYP and was always available for discussions on many detailed matters. Tillkännagivande • May 25
Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients with IBS at Massachusetts General Hospital Tryp Therapeutics Inc. announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its planned Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients aged 21+ suffering from Irritable Bowel Syndrome (IBS) at Massachusetts General Hospital (MGH). The planned open label study in collaboration with Harvard Medical School/Mass Massachusetts General Hospital will evaluate the effect of psilocybin- assisted psychotherapy in patients with treatment-resistant IBS who experience chronic abdominal pain and other debilitating gastrointestinal symptoms. Many of these patients also suffer from fibromyalgia, anxiety and fatigue. The primary efficacy endpoint of the study will be improvement in abdominal pain. The proposed study will also explore changes in brain connectivity and responses to pain at baseline and at four weeks, six months and twelve months post the psychedelic drug sessions, along with numerous other secondary endpoints. Tillkännagivande • Jan 06
Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder with Psilocybin-Assisted Psychotherapy Tryp Therapeutics Inc. announced interim results for the first five patients dosed in its Phase II STOP (Study of the Treatment of Overeating utilizing Psilocybin) trial. In collaboration with the University of Florida, the STOP trial is evaluating TRP-8802 (oral psilocybin) in patients with binge eating disorder ("BED") and represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with BED. Previously, Tryp reported that immediately following the post-dosing integration session with the trial's psychotherapists and throughout the four-week period post-dosing, the first patient in the STOP trial exhibited reduced overall anxiety, reduced anxiety around food, reduced compulsion to overeat and improved self-image and confidence. Analysis of the additional four patients has reinforced the initial clinical observations. The current results demonstrated a significant reduction in the frequency of binge eating behavior for each patient as measured in multiple assessments of efficacy which were discussed with the FDA as acceptable endpoints in advance of this study. In addition, analysis of the Hospital Anxiety and Depression Scale (HADS) anxiety and depression scores demonstrated improving trends related to patients' levels of anxiety and depression. The observed behavioral improvements are consistent with those described in other clinical studies examining the clinical benefit of psilocybin as a therapeutic intervention in compulsion-related disorders. There were no drug-related adverse events reported by these patients during the four-week period following dosing of TRP-8802. Tryp Therapeutics will be presenting at Biotech Showcase in San Francisco at 11am PT on Monday, January 9, and the presentation will include a review of this interim data. Price Target Changed • Nov 17
Price target decreased to CA$1.50 Down from CA$2.00, the current price target is provided by 1 analyst. New target price is 1,150% above last closing price of CA$0.12. Stock is down 59% over the past year. The company is forecast to post a net loss per share of CA$0.10 next year compared to a net loss per share of CA$0.16 last year. Tillkännagivande • Oct 06
Tryp Therapeutics Inc. Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin Tryp Therapeutics Inc. announced that the World Intellectual Property Organization (WIPO) published their international patent application (PCT/IB2022/052347) covering the intravenous administration of psilocybin and psilocin. The PCT application, titled “Improved Methods For The Use of Psychedelics” expands and strengthens the IP related to the Company’s development of TRP-8803, an IV formulation of psilocin, which will be administered in conjunction with psychotherapy. The patent application includes a unique and proprietary formulation and delivery system to enhance the positive effects of psilocybin and in particular psilocin, while markedly reducing the limitations of psilocybin dosed through other routes of administration, including oral, nasal and sublingual. Oral administration, while convenient, has several limitations and challenges that TRP-8803 can address, including: Controlling time to onset of psychedelic experience; Oral administration of psilocybin can take 1 to 2 hours to induce the psychedelic state; IV infusion can reduce this time period to within 30 minutes. Managing the duration of the psychedelic experience; With oral administration the psychedelic state, once started, can last 6-8 hours, a significant burden to the patient and the two psychotherapists; IV administration allows the practitioner to manage the duration of the psychedelic state and potentially shortens the overall duration to 1-2 hours. Achieving clinically validated blood levels of psilocin; When orally administered, psilocybin’s bioavailability can be reduced due to first pass metabolism in the liver. Psilocybin is a pro-drug which needs to be converted to psilocin, the active molecule that crosses the blood brain barrier and induces the psychedelic state. These factors contribute to variable blood levels of psilocin, which can be either too low or too high. High blood levels are associated with side effects, while low blood levels of psilocin can reduce efficacy; IV administration enables more precise dosing which achieves optimal blood levels of psilocin, thereby improving the likelihood of achieving clinical endpoints and efficacy while preserving safety. Customizing the psychedelic experience; IV administration provides more control over the experience, allowing the attending psychotherapist to increase or decrease both the strength and duration of the psychedelic experience. Conversely, should the patient experience a side effect, the clinician can terminate administration of the drug, an option not available with oral administration. With these advantages, particularly TRP-8803’s ability to reduce the time spent with medical professionals in a clinical setting, the Company believes there is a clear path to scaling broader commercial acceptance and use of TRP-8803 in conjunction with psychotherapy. Orally administered psychedelics have been widely introduced for use in treating depression, PTSD, OCD and other conditions, including by Tryp Therapeutics and its TRP-8802 programs. The Company plans to leverage its current clinical studies using TRP-8802 for the treatment of binge eating disorders and chronic pain to improve the likelihood of success for TRP-8803, with the additional goal of providing value to indications beyond those that Tryp is currently pursuing. Tillkännagivande • Sep 27
Tryp Therapeutics, Inc. Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803 Tryp Therapeutics Inc. announced the filing of two new provisional patent applications. One patent application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other application, #63/375,305, expands the IP related to the Company’s development of TRP-8803. The Company is preparing for a Phase 2a clinical trial in collaboration with the University of Michigan to investigate safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia. The clinical studies are expected to reinforce the positive preclinical results obtained by Tryp in an animal model of nociplastic pain. Once issued, the new patent will provide Tryp with Intellectual Property Protection for fibromyalgia utilizing its psilocybin-based candidates. About Fibromyalgia (FM). Fibromyalgia is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues; Existing treatments have limited efficacy and significant side effects; Fewer than 10% of patients adhere to approved treatments after one year; ~30% of patients take opioids despite the lack of evidence for efficacy and the risk of addiction and/or overdose. Tryp is utilizing TRP-8802 to evaluate the use of psilocybin-related compounds in certain neuropsychiatric disorders in early-stage trials. Tryp’s leading drug candidate TRP-8803, which is being developed concurrently, will be studied in subsequent trials where efficacy is indicated. TRP-8803 includes a unique formulation and delivery system to enhance the positive effects of psilocybin and psilocybin-related compounds, while markedly reducing the limitations of psilocybin dosed through other routes of administration, including oral, nasal and sublingual. The second provisional patent will expand the IP supporting TRP-8803 Tryp’s proprietary psilocybin- based product. The focus of the provisional patent application involves the development of salt forms and co-formers that improve the chemical properties of TRP-8803 thereby improving its stability and suitability for TRP-8803’s novel formulation and route of administration. Tillkännagivande • Sep 20
Tryp Therapeutics Appoints Jim O'Neill as Chief Financial Officer Tryp Therapeutics Inc. announced that it has expanded its leadership team with the appointment of Jim O'Neill as its Chief Financial Officer. In his new role, Mr. O'Neill will oversee all aspects of Tryp's finance and accountingorganization. The appointment of Mr. O'Neill follows the planned transition of Sid Taubenfeld from interim Chief Financial Officer, to his current role as Chief Operating Officer.Mr. O'Neill has over 30 years of experience as a finance executive with publicly listed and private multi-national businesses operating in Canada, the U.S., the UK, Turkey, and Kenya. Most recently, Mr. O'Neill founded and served as president of O'Neill & O'Neill Services Corp. providing financial consulting services including CFO and corporate secretarial services to TSXV and CSE listed companies as well as private businesses. Mr. O'Neill also previously served as chief financial officer for various public and private companies with responsibilities including cash flow management, fundraising, financing, investment analysis, and evaluating potential merger and acquisition opportunities. He received his bachelor's in business administration from Wilfrid Laurier University and holds a CPA and CA from the Chartered Professional Accountants of Canada. Board Change • Aug 31
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 2 experienced directors. No highly experienced directors. Co-Founder & Director Jim Kuo is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Jun 30
Tryp Therapeutics Inc. Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment Tryp Therapeutics Inc. announced the filing of a new provisional patent for the use of psilocybin for the treatment of patients with Binge Eating disorder (BED). The new patent application is part of Tryp's corporate strategy to expand the clinical utility of psilocybin-assisted therapy in patients with BED who are awaiting transformative medicines. Tryp's Phase II S.T.O.P. (Study of the Treatment of Overeating utilizing Psilocybin) trial in collaboration with the University of Florida, represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with BED. The initial data readout for the first patient dosed in the STOP trial showed potential benefit for patients with BED, further supporting the Company's commitment to developing psilocybin based therapies for patients with eating disorders. Once issued, the new patent will provide Tryp with an Intellectual Property Protection for BED utilizing its psilocybin-based candidates TRP-8802 and TRP-8803. Tryp is utilizing TRP-8802 to evaluate the use of psilocybin-related compounds in certain neuropsychiatric disorders in early-stage trials. In disorders where efficacy is indicated, Tryp's lead drug candidate TRP-8803 which is being developed concurrently, will be studied in subsequent trials. TRP-8803 includes a unique formulation and delivery system and is designed to enhance the positive effects of psilocybin and psilocybin-related compounds, while markedly reducing the limitations of psilocybin dosed through other routes of administration, including oral, nasal and sublingual. About Binge Eating Disorder (BED): BED is characterized by recurring episodes of eating large quantities of food and feeling unable to stop; Nearly 30% of people seeking weight loss treatments show signs of BED and Up to 3.5% of females and 2.0% of males will develop BED at some point in their lives - nearly 4 million women and 2 million men in the United States; treatments to date have not been effective. Tillkännagivande • Jun 24
Tryp Therapeutics Appoints Sid Taubenfeld as Chief Operating Officer Tryp Therapeutics Inc. announced that Sid Taubenfeld, a seasoned executive with healthcare and biotech expertise, has joined the Company's senior leadership team as Chief Operating Officer. Taubenfeld is a forward-thinking leader with over 20 years of significant experience in senior leadership roles and a deep understanding of scientific, financial, and commercial strategy. Most recently, he served as the CEO of Tikun Olam Pharma (TOP), a leading medical cannabis company based in Israel. Sid's primary responsibilities will include developing the organization's long-term vision and strategy alongside the CEO and Board; ensuring that the company operates effectively and efficiently in all areas; and helping ensure a high-performing portfolio and psychedelic medicine advancements at Tryp. Previously, Taubenfeld gained extensive pharmaceutical experience in a variety of executive management roles in the United States and Israel. He graduated from Brooklyn College of Pharmacy with a B.S. in Pharmacy and completed his graduate studies at New York Medical College in the area of Pharmacology. Tillkännagivande • Jun 10
Tryp Therapeutics Inc. Announces Results of First Patient Dosed in its Phase II Clinical Trial for the Treatment of Binge Eating Disorder Tryp Therapeutics Inc. announced the initial data readout for the first patient dosed in its Phase II S.T.O.P. trial. In collaboration with the University of Florida. The STOP trial is evaluating TRP-8802 in patients with Binge Eating Disorder and represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with BED. Beginning immediately following the post-dosing integration session with the trial's psychotherapists and persisting throughout the four-week time period post-dosing, the first patient in the STOP trial exhibited reduced overall anxiety; reduced anxiety around food; reduced compulsion to overeat; and improved self-image and confidence. These positive changes in behavior translated to significant weight loss at four weeks. The observed behavioral improvements are consistent with those described in other clinical studies examining the clinical benefit of psilocybin as a therapeutic intervention in neuro-psychiatric disorders. In addition, it is important to note there were no drug-related adverse events observed during the 4-week period following dosing of TRP-8802. Pursuant to the STOP trial protocol, patients will be monitored for an additional eight weeks post-dosing, TRP-8802 is the predecessor to Tryp's lead psilocybin-based drug candidate, TRP-8803. TRP-8803 includes a unique formulation and delivery system and is designed to enhance the positive effects of psilocybin and psilocybin-related compounds, while markedly reducing the limitations of psilocybin dosed through other routesof administration. In combination with psychotherapy, TRP-8803 is intended to serve as a treatment for certain neuropsychiatric disorders including BED. Tryp is utilizing TRP-8802 to evaluate the use of psilocybin-related compounds in certain neuropsychiatric disorders in early-stage trials. If initial efficacy is shown, TRP-8803 will be studied in future trials. Tillkännagivande • May 26
Tryp Therapeutics Inc. Appoints Chris Ntoumenopoulos to Board of Directors Tryp Therapeutics Inc. announced the appointment of Chris Ntoumenopoulos to the Company's Board of Directors. Ntoumenopoulos comes to Tryp with extensive experience in financial markets both in raising capital and corporate strategy. He currently serves as the Managing Director at 21 Corporate, an Australia-based Corporate Advisory firm which provides funding and corporate support for innovative companies and technologies. In addition, Ntoumenopoulos is a strategic investment adviser at Freeman Road, an investment group specializing in health and early-stage MedTech companies. Ntoumenopoulos also serves as Director of ResApp Diagnostics (RAP), a respiratory diagnostic company focusing on digital medicine, and as Director of ASX listed Race Oncology (RAC). Price Target Changed • Apr 27
Price target decreased to CA$1.50 Down from CA$2.00, the current price target is provided by 1 analyst. New target price is 2,043% above last closing price of CA$0.07. Stock is down 90% over the past year. The company is forecast to post a net loss per share of CA$0.14 next year compared to a net loss per share of CA$0.16 last year. Tillkännagivande • Apr 24
Tryp Therapeutics Inc., Annual General Meeting, Jun 23, 2022 Tryp Therapeutics Inc., Annual General Meeting, Jun 23, 2022. Recent Insider Transactions • Feb 24
Insider recently bought CA$1.0m worth of stock On the 22nd of February, William Garner bought around 5m shares on-market at roughly CA$0.20 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$1.1m more in shares than they have sold in the last 12 months. Tillkännagivande • Feb 24
Tryp Therapeutics Inc. Announces Board Changes Tryp Therapeutics Inc. announced that Mr. David L. Tousley, CPA, MBA, has been appointed as a new independent director to replace William Garner, M.D., who stepped down from the Tryp Board of Directors in connection with his investment in the Company's previously announced non-brokered private placement (the "Private Placement"). Tillkännagivande • Dec 24
Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder Tryp Therapeutics announced the receipt of correspondence from the U.S. Food and Drug Administration (FDA) affirming the Company's ability to proceed with a Phase 2a clinical trial evaluating the use of synthetic psilocybin for binge eating disorder. Tryp previously announced on October 20, 2021 a clinical hold placed on the study by the FDA. The Company provided an update on the matter on November 18, 2021 and submitted an amendment to the FDA for the Investigational New Drug (IND) application on December 9, 2021. Through the notice received this week, the FDA removed the clinical hold and advised Tryp that it can continue with the study. Tillkännagivande • Dec 03
Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia Tryp Therapeutics announced that it has received confirmation from the U.S. Food and Drug Administration ("FDA") that its review of Tryp's Investigational New Drug ("IND") application is complete and that the Company may proceed with its clinical study in fibromyalgia. The trial is being conducted with Kevin Boehnke, Ph.D. from the University of Michigan and will evaluate the Company's oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. Tryp expects to initiate the Phase 2a study in 2022. The Phase 2a open label clinical trial will enroll 20 fibromyalgia patients and includes a variety of secondary and exploratory endpoints given the high prevalence of co-morbidities such as poor sleep quality, depression, anxiety, and other conditions in patients suffering from fibromyalgia. The administration of psilocybin is expected to increase neuroplasticity and to address disrupted neural connections that have been reported for nociplastic pain indications. The clinical trial will be one of the first evaluations of synthetic psilocybin for fibromyalgia in a Phase 2 study. Tillkännagivande • Sep 24
Tryp Therapeutics Submits IND Application for Phase 2A Clinical Trial in Eating Disorders Tryp Therapeutics announced that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration ("FDA") to evaluate its clinical candidate, TRP-8802, in a Phase 2a study for the treatment of patients with eatingdisorders. The trial is being conducted with Jennifer Miller, M.D., from the University of Florida and will evaluate the Company's oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. TheIND application includes details regarding the safety of the drug product, the protocol for the study, the informed consent information for patients, and other information. Tryp expects to initiate the Phase 2astudyin Fourth Quarter of this year subject to a favorable review of the IND by the FDA. The Phase 2a clinical trial is expected to enroll 10 patients with various overeating disorders including binge eating disorder, hypothalamic obesity, and Prader-Willi Syndrome. The administration of psilocybin is expected to increase neuroplasticity and help create healthy neural patterns related to hunger and eating. Patients will meet with psychotherapists who have been trained by Fluence for two sessions prior to the administration of TRP-8802, which will take place in two drug-dosing sessions. Integration sessions with the psychotherapists will be conducted after the administration of the drug. Tillkännagivande • Sep 01
Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida Tryp Therapeutics announced that it has completed the training of psychotherapists for its upcoming Phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for overeating disorders. The training was conducted by Fluence, which is led by researchers and psychotherapists with direct experience in psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic compounds to patients. Tryp believes that both pharmaceutical and psychological processes will play a synergistic role to determine outcomes for TRP-8802, an oral formulation of synthetic psilocybin. Psychotherapy is an integral part of Tryp's novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming Phase 2a clinical trial for eating disorders, conducted at the University of Florida with Jennifer Miller, M.D. Following the administration of the drug, patients will also benefit from multiple integration sessions with the therapists. Tryp Therapeutics, Fluence and the University of Florida have collaborated to create a comprehensive training manual for the psychotherapy portion of Tryp's psychedelic treatment regimen that will be adapted for subsequent clinical trials in fibromyalgia and other chronic pain indications. Recent Insider Transactions • Aug 29
MD, Founder & Executive Director recently bought CA$65k worth of stock On the 25th of August, William Garner bought around 185k shares on-market at roughly CA$0.35 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$70k more in shares than they have sold in the last 12 months. Tillkännagivande • Jul 23
Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan Tryp Therapeutics Inc. announced its plans to conduct a Phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department
of Anesthesiology at the University of Michigan Medical School. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia. The treatment is designed to target nociplastic pain originating in the central nervous system through the neuroplasticity benefits of psilocybin. The Principal Investigator for the trial will be Kevin Boehnke, Ph.D., Research Investigator, University of Michigan Department of Anesthesiology. Tryp will seek to identify a response in patients to the treatment to inform the design of a Phase 2b clinical trial for fibromyalgia that will use the company's proprietary, psilocybin-based drug product, TRP-8803, that includes a novel formulation and unique method of delivery. Fibromyalgia is a disease of the central nervous system that is estimated to affect as much as 2% to 8% of the population. The disease is characterized by widespread pain commonly accompanied by fatigue, memory problems, and sleep disturbances. With available treatment options often proving ineffective, nearly 30% of fibromyalgia patients alarmingly resort to opioid-based medications in an attempt to address symptoms of pain stemming from the disease. Tryp expects to submit the Investigational New
Drug (IND) application to the FDA for the Phase 2a clinical trial in Third Quarter 2021. Tillkännagivande • Mar 11
Tryp Therapeutics Inc. Appoints Luke Hayes as Chief Financial Officer Tryp Therapeutics Inc. announced that it has appointed Luke Hayes as its Chief Financial Officer. Mr. Hayes has been active in the life science industry for more than 20 years with experience in technology transfer, venture capital, and finance. He started his career doing business development for Dow Chemical with responsibility for pharmaceutical customers including Lilly and AbbVie. He spent more than a decade doing venture capital investing while supporting a wide range of companies as a Director and advisor. Mr. Hayes has deep experience with corporate finance and capital formation activities as well as extensive relationships throughout the life science industry. Tillkännagivande • Feb 12
Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor Tryp Therapeutics announced that it has executed an advisory agreement with Dr. Joel Castellanos to join the company's Scientific Advisory Board. He will guide Tryp's clinical development of TRP-8802 for neuropathic pain indications. Dr. Joel Castellanos, MD, is a board-certified physical medicine and rehabilitation physician who is fellowship trained in pain medicine. Dr Castellanos is a member of the "Psychedelics and Health Research Initiative" at UC San Diego "PHRI", a collaborative endeavor cutting across multiple divisions and departments of UC San Diego. Dr. Castellano is also an associate professor in the Department of Anesthesiology at UC San Diego School of Medicine, Dr. Castellanos instructs pain medicine fellows, as well as medical students, and residents in their pain rotations. Dr. Castellanos completed his fellowship in pain medicine at UC San Diego School of Medicine. Tillkännagivande • Feb 10
Tryp Therapeutics Plans Phase 2A Eating Disorder Clinical Trial with Dr. Jennifer Miller Tryp Therapeutics announced it has commenced a collaboration with Dr. Jennifer Miller of the University of Florida as the Principal Investigator for a clinical trial to treat the symptoms associated with eating disorders. Tryp and Dr. Miller have begun designing a Phase 2a open-label, exploratory clinical study utilizing TRP-8802 in patients suffering from rare and orphan over-eating disorders. Dr. Miller is a Professor in the division of pediatric endocrinology at University of Florida. She received her M.D. and her M.S. in Clinical Investigation from the University of Florida. She further trained in pediatrics and pediatric endocrinology at the University of Florida. Dr. Miller specializes in the care and treatment of individuals with Prader-Willi syndrome and other genetic causes of early-onset excessive weight gain. Tillkännagivande • Feb 06
Tryp Therapeutics Inc. announced that it expects to receive CAD 2 million in funding Tryp Therapeutics Inc. (CNSX:TRYP) announced a non-brokered private placement of 3,333,333 units at a price of CAD 0.60 per unit for gross proceeds of approximately CAD 2,000,000 on February 5, 2021. The transaction will lead by Marc Lustig. Each unit consists of one common share and one-half of one common share purchase warrant. Each warrant entitles the holder to acquire one additional common share at a price of CAD 0.75 per common share for a period of 24 months from the date of issuance. Closing of the placement is anticipated to occur on or about February 12, 2021. The transaction is subject to receipt of all necessary corporate and regulatory approvals, including the approval of the Canadian Securities Exchange. The securities issued pursuant to the placement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. Tillkännagivande • Feb 04
Tryp Therapeutics Announces the Appointment of Greg Mckee as Executive Chairman Tryp Therapeutics announced the appointment of Greg McKee as Executive Chairman. Mr. McKee joined the Board in January of 2021 and brings more than 20 years of biotechnology, life sciences management and venture investment experience to the company. In connection with his appointment, Mr. McKee has been granted an aggregate of 2,000,000 stock options. The Options have an exercise price of $0.70 per share, are exercisable until January 13, 2031 and will be governed in accordance with the terms of the Company's stock option plan. Tillkännagivande • Feb 03
Tryp Therapeutics Inc. Appoints Robin Carhart Harris to Scientific Advisory Board Tryp Therapeutics announced that it has added world renowned psychedelic scientist, Dr. Robin Carhart Harris to help lead its Scientific Advisory Board. Dr. Carhart-Harris is the Head of the Centre for Psychedelic Research in the Department of Brain Sciences at Imperial College London where he has published numerous clinical trials studying the effects of psychedelics on the brain. While there, he has designed a number of functional brain imaging studies with psilocybin (magic mushrooms), LSD, MDMA (ecstasy) and DMT (ayahuasca). Dr. Carhart-Harris has over 90 published papers in peer-reviewed scientific journals; 5 of which rank in the top 10 for annual citation rate in the field of psychedelic science, including the top 2 overall. Robin's research has featured in major national and international media and he has given a popular TEDx talk and has been a leading voice for psychedelic medicine at the World Economic Forum in Davos. His talks on psychedelic-assisted therapy play a significant role in the development of psychedelics as novel pharmaceuticals for the treatment of disorders currently underserved with existing therapies and he will play a crucial role in helping to shape Tryp's upcoming clinical trials. Tillkännagivande • Jan 23
Tryp Therapeutics Inc., Annual General Meeting, Mar 24, 2021 Tryp Therapeutics Inc., Annual General Meeting, Mar 24, 2021. Tillkännagivande • Jan 15
Tryp Therapeutics Inc. Appoints Gregory M. Mckee to the Board of Directors Tryp Therapeutics Inc. announced the appointment of Gregory M. McKee to the Company’s board of directors. Before joining Tryp, he founded Torrent Ventures, an early stage digital health and medical technology venture fund, and served as chief executive officer of CONNECT. Tillkännagivande • Jan 09
Tryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory Board Tryp Therapeutics announced it has appointed Dr. William K. Schmidt, a noted authority in the development of pain drugs, as a Scientific Advisory Board member. Dr.
Schmidt, will aid Tryp in the development of its product candidate TRP-8802 for fibromyalgia and other chronic pain conditions. Tillkännagivande • Dec 23
Tryp Therapeutics Inc. Appoints Dr. Peter Guzzo as Its Vice President of Drug Development Tryp Therapeutics Inc. announced it has appointed Dr. Peter Guzzo as its Vice President of Drug Development. Dr. Guzzo has devoted his entire 25-year professional career to innovative therapeutics for poorly treated diseases. He has been involved in drug discovery, clinical research, and executive level roles. He has led cross-functional teams that delivered eleven innovative drugs into clinical development. His experience collaborating with pharma, biotech, academic institutions and contract research organizations will help to execute and push forward drug development pipeline. Dr. Guzzo has broad knowledge in several therapeutic indications including central nervous system diseases, metabolic disorders and oncology, intellectual property creation, and building entrepreneurial teams. He is an inventor on 43 patents, co-authored 47 scientific publications, and presented 28 invited lectures. Tillkännagivande • Dec 19
Tryp Therapeutics Inc. has completed an IPO in the amount of CAD 4.35 million. Tryp Therapeutics Inc. has completed an IPO in the amount of CAD 4.35 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Price\Range: CAD 0.25
Discount Per Security: CAD 0.02
Security Name: Units
Security Type: Equity/Derivative Unit
Price\Range: CAD 0.25
Discount Per Security: CAD 0.01